On May 8, 2025, Guggenheim analyst Michael Schmidt announced a revision in the price target for BeiGene (ONC, Financial), maintaining a "Buy" rating. The updated price target is set at USD 350.00, up from the prior target of USD 348.00, reflecting a modest increase of 0.57%.
Guggenheim's decision to maintain the "Buy" rating for BeiGene (ONC, Financial) underscores confidence in its market performance. The slight adjustment in the price target further signifies positive expectations for the stock's future valuation.
BeiGene (ONC, Financial) continues to be observed closely by investors and market analysts as it remains an active contender in the market, following the latest adjustments from Guggenheim. The revised price target aligns with the company's growth prospects and anticipated market developments.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 23 analysts, the average target price for BeiGene Ltd (ONC, Financial) is $277.93 with a high estimate of $376.00 and a low estimate of $207.00. The average target implies an upside of 19.38% from the current price of $232.82. More detailed estimate data can be found on the BeiGene Ltd (ONC) Forecast page.
Based on the consensus recommendation from 24 brokerage firms, BeiGene Ltd's (ONC, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for BeiGene Ltd (ONC, Financial) in one year is $549.01, suggesting a upside of 135.81% from the current price of $232.82. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the BeiGene Ltd (ONC) Summary page.
